[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@AVDB2171](/creator/twitter/AVDB2171)
"Novartis just committed $5B+ in options to a biotech founded only X years ago. No approved products. No late-stage trials. Just one innovation engine that made Novartis double down. Heres why this deal could shape the future of cardiometabolic medicine:"  
[X Link](https://x.com/AVDB2171/status/1973398762711294275) [@AVDB2171](/creator/x/AVDB2171) 2025-10-01T14:45Z XXX followers, 8587 engagements


"Roche & Jazz Pharma just secured FDA approval for the first-ever maintenance therapy in small cell lung cancer. A breakthrough in one of the most aggressive cancers a field thats seen almost no new progress in decades. Heres why this milestone matters far beyond oncology:"  
[X Link](https://x.com/AVDB2171/status/1976290322364928116) [@AVDB2171](/creator/x/AVDB2171) 2025-10-09T14:15Z XXX followers, 5863 engagements


"AstraZeneca has been steadily expanding its AI footprint. In 2025 alone it announced: a $5.3B AI deal with CSPC a $200M oncology partnership with Tempus & Pathos AI And now they just made one of their boldest platform bets yet:"  
[X Link](https://x.com/AVDB2171/status/1979189461654344056) [@AVDB2171](/creator/x/AVDB2171) 2025-10-17T14:15Z XXX followers, XXX engagements


"AstraZeneca just signed a $555M partnership with Algen Biotechnologies a San Francisco biotech with zero approved products. What did they see A platform so powerful it could generate dozens of drug targets continuously. Here's the play behind the price:"  
[X Link](https://x.com/AVDB2171/status/1979189476632203648) [@AVDB2171](/creator/x/AVDB2171) 2025-10-17T14:15Z XXX followers, XX engagements


"Algen's platform is called AlgenBrain. It combines AI with CRISPR-based functional genomics to map how genes regulate immune pathways. This identifies potential drug targets that traditional discovery methods often miss. But it's more than just target identification"  
[X Link](https://x.com/AVDB2171/status/1979189491475825013) [@AVDB2171](/creator/x/AVDB2171) 2025-10-17T14:15Z XXX followers, XX engagements


"These aren't one-off discoveries. AlgenBrain is a discovery engine that can continuously generate new targets for immune-mediated diseases. That means multiple shots on goal not just a single product. Thats why AstraZeneca entered a $555M milestone-based partnership"  
[X Link](https://x.com/AVDB2171/status/1979189503974871076) [@AVDB2171](/creator/x/AVDB2171) 2025-10-17T14:15Z XXX followers, XX engagements


"For a partnership with no clinical data that's rare. But this wasn't a product bet. It was a platform bet and a strategic one at that. So what did AstraZeneca actually buy"  
[X Link](https://x.com/AVDB2171/status/1979189520269730123) [@AVDB2171](/creator/x/AVDB2171) 2025-10-17T14:15Z XXX followers, XX engagements


"Under the deal: Algen identifies and validates new immunology targets AstraZeneca gains exclusive rights to develop therapies against them Total value up to $555M in upfront and milestone payments No molecules changed hands. No compounds. No clinical candidates"  
[X Link](https://x.com/AVDB2171/status/1979189532634550313) [@AVDB2171](/creator/x/AVDB2171) 2025-10-17T14:15Z XXX followers, XX engagements


"Target identification is one of the least predictable phases of R&D. Platforms like Algen's can shorten that timeline lower attrition and strengthen first-in-class potential across multiple indications. This wasn't tactical. It was architectural"  
[X Link](https://x.com/AVDB2171/status/1979189561843683548) [@AVDB2171](/creator/x/AVDB2171) 2025-10-17T14:15Z XXX followers, XX engagements


"The deal structure itself tells you everything. Milestone-based payments align both sides on long-term success while limiting AstraZeneca's risk. For Algen it brings validation capital and access to AstraZeneca's translational expertise and datasets. How does this potentially impact long term M&A prospects in the biopharma industry"  
[X Link](https://x.com/AVDB2171/status/1979189573902368862) [@AVDB2171](/creator/x/AVDB2171) 2025-10-17T14:15Z XXX followers, XX engagements


"Pharma companies are moving upstream. They're partnering with AI platforms to build continuous discovery capacity rather than buying late-stage assets. It's a strategic shift from product acquisition to capability acquisition. What made this deal possible"  
[X Link](https://x.com/AVDB2171/status/1979189590297841729) [@AVDB2171](/creator/x/AVDB2171) 2025-10-17T14:15Z XXX followers, XX engagements


"Biotech deal flow and market trends are complex but approachable with the right guidance. At we support leaders navigating these challenges with authentic insightful content. Follow me @AVDB2171 for more on biotech M&A market shifts & strategy"  
[X Link](https://x.com/AVDB2171/status/1979189649894707518) [@AVDB2171](/creator/x/AVDB2171) 2025-10-17T14:15Z XXX followers, XX engagements


"Media Used:"  
[X Link](https://x.com/AVDB2171/status/1979189661647147273) [@AVDB2171](/creator/x/AVDB2171) 2025-10-17T14:16Z XXX followers, XX engagements


"#3: Prolia/Xgeva (Amgen) - $4.39B U.S. sales Amgen long a leader in biosimilars now faces denosumab biosimilars itself. Sandoz launches May 31st Celltrion June 1st. It's a reminder that no franchise is immune moats in this industry are always temporary"  
[X Link](https://x.com/AVDB2171/status/1961116761283334633) [@AVDB2171](/creator/x/AVDB2171) 2025-08-28T17:20Z XXX followers, 1294 engagements


"Glenmark just signed a $1.1B licensing deal with Chinas Hengrui Pharma. No U.S. or EU rights. No Big Pharma intermediaries. Just two emerging-market leaders building a new model for global biotech. Heres why this deal matters more than it seems:"  
[X Link](https://x.com/AVDB2171/status/1978109812622893504) [@AVDB2171](/creator/x/AVDB2171) 2025-10-14T14:45Z XXX followers, 9957 engagements


"For years antibodydrug conjugates (ADCs) were the Wests domain. Then came Enhertu: AstraZeneca and Daiichis $3.7B blockbuster proving how powerful targeted payloads could be. Now Asia wants in on the next wave"  
[X Link](https://x.com/AVDB2171/status/1978109824954175577) [@AVDB2171](/creator/x/AVDB2171) 2025-10-14T14:45Z XXX followers, XXX engagements


"Deal terms: $18M upfront $1.09B in milestones Royalties on sales For Glenmark: a credible oncology entry. For Hengrui: expansion without overextending. Everyone plays to their strengths"  
[X Link](https://x.com/AVDB2171/status/1978110044341493780) [@AVDB2171](/creator/x/AVDB2171) 2025-10-14T14:46Z XXX followers, XXX engagements


"This isnt Hengruis first major partnership. In the past XX months: $12B+ multi-asset deal with GSK $2B cardiovascular partnership with Merck Chinas innovators arent copying anymore theyre exporting"  
[X Link](https://x.com/AVDB2171/status/1978110110942855251) [@AVDB2171](/creator/x/AVDB2171) 2025-10-14T14:46Z XXX followers, XX engagements


"AstraZeneca just made a $555M AI pact with a San Francisco biotech. No clinical programs. No approved drugs. Just ONE thing that made every boardroom take notice. Here's why it could reshape how Big Pharma discovers therapies:"  
[X Link](https://x.com/AVDB2171/status/1979189446655512797) [@AVDB2171](/creator/x/AVDB2171) 2025-10-17T14:15Z XXX followers, 6412 engagements


"Novo Nordisk just doubled down on MASH with a $5.2B acquisition that could define its post-GLP-1 era. This isnt diversification. Its focus. Heres why the deal may shape the next decade of cardiometabolic medicine:"  
[X Link](https://x.com/AVDB2171/status/1980276585807974458) [@AVDB2171](/creator/x/AVDB2171) 2025-10-20T14:15Z XXX followers, 8235 engagements


"Novo Nordisk just made its first major move under new CEO Mike Doustdar: A $5.2B acquisition of Akero Therapeutics a U.S. biotech developing advanced therapies for liver disease. The deal terms:"  
[X Link](https://x.com/AVDB2171/status/1980276600244674591) [@AVDB2171](/creator/x/AVDB2171) 2025-10-20T14:15Z XXX followers, XX engagements


"$4.7B upfront at $54/share $500M milestone tied to FDA approval by mid-2031 Financed through debt Expected to close by year-end But the strategic logic matters more than the structure"  
[X Link](https://x.com/AVDB2171/status/1980276615289708991) [@AVDB2171](/creator/x/AVDB2171) 2025-10-20T14:15Z XXX followers, XX engagements


"Novo called it an important building block for future growth. Analysts see it as a critical asset for Novos metabolic franchise. MASH sits at the intersection of obesity diabetes and liver disease all areas where Novo already leads with its GLP-1 portfolio"  
[X Link](https://x.com/AVDB2171/status/1980276642699481404) [@AVDB2171](/creator/x/AVDB2171) 2025-10-20T14:15Z XXX followers, XX engagements


"So this deal isnt diversification. Its an expansion of Novos metabolic ecosystem. The competitive landscape is heating up"  
[X Link](https://x.com/AVDB2171/status/1980276658289664436) [@AVDB2171](/creator/x/AVDB2171) 2025-10-20T14:15Z XXX followers, XX engagements


"Novo shares have risen XX% since Doustdars appointment though still down XX% YTD. Investors remain cautious but the market rewarded Akero with a XX% spike on announcement day. The signal is clear: high conviction in the asset class"  
[X Link](https://x.com/AVDB2171/status/1980276741248811247) [@AVDB2171](/creator/x/AVDB2171) 2025-10-20T14:15Z XXX followers, XX engagements


"3 Takeaways for Biopharma Leaders: Depth Diversification. Novo stayed in its lane and went deeper. De-risked assets still move the needle when timed to patent cliffs. MASH is the next cardiometabolic frontier: whoever wins payer access first wins the decade"  
[X Link](https://x.com/AVDB2171/status/1980276753617875311) [@AVDB2171](/creator/x/AVDB2171) 2025-10-20T14:15Z XXX followers, XX engagements


"This deal reinforces Novos playbook: focus beats diversification. Doustdars first move shows conviction acquiring where they already lead not chasing new categories. Strategic continuity often outperforms reinvention"  
[X Link](https://x.com/AVDB2171/status/1980276765437440430) [@AVDB2171](/creator/x/AVDB2171) 2025-10-20T14:15Z XXX followers, XX engagements